Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

IL-18-producing Salmonella inhibit tumor growth

Abstract

Previous studies have shown that intravenously applied bacteria can accumulate in tumors and lead to sporadic tumor regression. Recently, systemic administration of attenuated Salmonella typhimurium was demonstrated to generate no significant side effects in humans, but also no antitumor responses. We report the enhanced antitumor activity in preclinical mouse cancer models of nonvirulent S. typhimurium engineered to synthesize the cytokine Interleukin-18 (IL-18). IL-18-producing bacteria (but not control bacteria) inhibit the growth of primary subcutaneous tumors as well as pulmonary metastases in immunocompetent mice challenged with syngeneic multidrug-resistant clones of murine carcinoma cell lines, without overt toxicity to normal tissues. Antitumor activity was associated with increased accumulation of T-lymphocytes and NK cells in tumors, and massive infiltration of granulocytes, as well as increased intra-tumoral production of several cytokines. In summary, these findings provide evidence of promising preclinical antitumor activity of IL-18-expressing, attenuated S. typhimurium, suggesting a novel strategy for cancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Coley WB . The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop 1893; 262: 3–11.

    Google Scholar 

  2. Coley W . Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigosus. Am J Med Sci 1906; 131: 375–430.

    Google Scholar 

  3. Coley W . Melanotic cancer. Ann Surg 1916; 64: 206–241.

    Article  CAS  Google Scholar 

  4. Herr HW . Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 762–765.

    Article  CAS  Google Scholar 

  5. Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O'Donnell MA et al. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 1998; 159: 1054–1063.

    Article  CAS  Google Scholar 

  6. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000; 181: 1996–2002.

    Article  CAS  Google Scholar 

  7. Rosenberg SA, Spiess PJ, Kleiner DE . Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218–225.

    Article  CAS  Google Scholar 

  8. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142–152.

    Article  Google Scholar 

  9. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313–320.

    Article  CAS  Google Scholar 

  10. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005; 11: 4827–4834.

    Article  CAS  Google Scholar 

  11. Carrier MJ, Chatfield SN, Dougan G, Nowicka UT, O'Callaghan D, Beesley JE et al. Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol 1992; 148: 1176–1181.

    CAS  PubMed  Google Scholar 

  12. Marwick C . FDA halts gene therapy trials after leukaemia case in France. Bmj 2003; 326: 181.

    Article  Google Scholar 

  13. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88–91.

    Article  CAS  Google Scholar 

  14. Tough DF, Borrow P, Sprent J . Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947–1950.

    Article  CAS  Google Scholar 

  15. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157: 3967–3973.

    CAS  PubMed  Google Scholar 

  16. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H . Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423–474.

    Article  CAS  Google Scholar 

  17. Wigginton JM, Lee JK, Wiltrout TA, Alvord WG, Hixon JA, Subleski J et al. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002; 169: 4467–4474.

    Article  CAS  Google Scholar 

  18. Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, Kurimoto M et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 1999; 6: 808–815.

    Article  CAS  Google Scholar 

  19. Cao R, Farnebo J, Kurimoto M, Cao Y . Interleukin-18 acts as an angiogenesis and tumor suppressor. Faseb J 1999; 13: 2195–2202.

    Article  CAS  Google Scholar 

  20. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M . Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997; 57: 4557–4563.

    CAS  PubMed  Google Scholar 

  21. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 583–589.

    CAS  PubMed  Google Scholar 

  22. Woldbaek PR, Sande JB, Strømme TA, Lunde PK, Djurovic S, Lyberg T et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005; 289: H708–H714.

    Article  CAS  Google Scholar 

  23. Loeffler M, Le’negrate G, Krajewska M, Reed JC . Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 2007; 104: 12879–12883.

    Article  CAS  Google Scholar 

  24. Luo Y, Zhou H, Mizutani M, Mizutani N, Liu C, Xiang R et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res 2005; 65: 3419–3427.

    Article  CAS  Google Scholar 

  25. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755–760.

    Article  CAS  Google Scholar 

  26. Agorio C, Schreiber F, Sheppard M, Mastroeni P, Fernandez M, Martinez MA et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9: 416–423.

    Article  CAS  Google Scholar 

  27. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R . Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA 2003; 100: 8850–8855.

    Article  CAS  Google Scholar 

  28. Dinarello CA . The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20 (5 Suppl 27): S1–13.

    CAS  PubMed  Google Scholar 

  29. Reed JC, Doctor KS, Godzik A . The domains of apoptosis: a genomics perspective. Sci STKE 2004; 2004: re9.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Wei-Zen Wei for the D2F2 cell line, and acknowledge the generous support of the Austrian Academy of Sciences, APART Fellowship Program (ML) and the NIH (CA-69381) (JCR).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J C Reed.

Additional information

Supplementary Information accompanies the paper on Cancer Gene Therapy website (http://www.nature.com/cgt)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loeffler, M., Le'Negrate, G., Krajewska, M. et al. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther 15, 787–794 (2008). https://doi.org/10.1038/cgt.2008.48

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2008.48

Keywords

This article is cited by

Search

Quick links